Press

Safe Supply and Origin Therapeutics Announces Engagement of Research Capital and Upsizing of Brokered Financing To $4 Million

Mar 7 • 4 min read

Safe Supply Streaming Co. Ltd. and Origin Therapeutics Holdings Inc. (CSE: ORIG | FSE: U8B) are pleased to announce the upsizing of their previously disclosed private placement offering of subscription receipts (the “Subscription Receipts”) from $3 million to $4 million in aggregate gross proceeds. The Offering is being led by Research Capital Corporation as the…

Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Mar 6 • 3 min read

Incannex Healthcare Limited (Nasdaq: IXHL | ASX: IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Catalent (‘Catalent’) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and…

Mydecine Announces Debt Settlements

Mar 6 • 2 min read

Mydecine Innovations Group Inc. (NEO:MYCO | OTC:MYCOF | FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements for debt owed to certain arms-length creditors, service providers and debtors of the…

Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership

Mar 6 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF |OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, and PharmAla Biotech Holdings Inc (CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, today announced…

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Mar 6 • 5 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates. “The dosing of the first patient in the phase 2b study of RL-007 in CIAS earlier this quarter exemplifies the execution capabilities of our team as we advance our programs into…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441